Paper Details

  1. Home
  2. Paper Details

Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenib‑resistant melanoma cell lines.

Author: AbeNaoko, BannoYoshiko, KanohHiroyuki, SeishimaMariko, TakahashiTomoko

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Vemurafenib is a medication used to treat melanoma, but resistance to the drug is a significant concern. This study investigated the combination of vemurafenib and fingolimod, a sphingosine-1-phosphate receptor modulator, in treating vemurafenib-resistant melanoma cells. The combination showed synergistic effects in reducing cell viability and inducing apoptosis, suggesting a potential therapeutic strategy for overcoming vemurafenib resistance.
Paper Details　
Original Abstract of the Article :
Vemurafenib, a selective inhibitor of mutated BRAF, is used to treat late‑stage melanoma. However, resistance to vemurafenib is urgently required as it can have fatal consequences. Fingolimod (FTY720), a sphingosine‑1‑phosphate receptor modulator, has been used for the treatment of several malignant...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3892/mmr.2018.9537

データ提供：米国国立医学図書館（NLM）

Fighting Melanoma: A New Oasis in the Desert of Vemurafenib Resistance

Vemurafenib is a valuable weapon in the fight against melanoma, but resistance to this drug is a major challenge. This study explores a potential solution, investigating the synergistic effects of combining vemurafenib with fingolimod (FTY720) in vemurafenib-resistant melanoma cell lines. The researchers discovered that this combination treatment effectively induced cell death in resistant cell lines, a significant step forward in overcoming the desert of drug resistance.

Synergistic Effects: A New Oasis in the Desert of Resistance

The study reveals that combining vemurafenib with fingolimod effectively combats resistance, offering a promising new avenue for treating melanoma. The synergistic effects of this combination treatment demonstrate a powerful approach to overcoming the challenges of drug resistance, a significant step forward in the desert of melanoma research.

Navigating the Desert of Melanoma Treatment

This research highlights the importance of seeking innovative solutions in the face of drug resistance. The findings suggest that combining vemurafenib with fingolimod offers a promising approach to overcoming resistance, a crucial strategy in the desert of melanoma treatment. This research emphasizes the need for ongoing research and development of new therapeutic strategies to combat this challenging disease.

Dr.Camel's Conclusion

The desert of melanoma treatment can be a challenging landscape, but this research offers a glimmer of hope with the combination of vemurafenib and fingolimod. The synergistic effects of this combination demonstrate a powerful approach to overcoming drug resistance, a significant step forward in the fight against melanoma. This research encourages further exploration of this potential oasis in the desert of melanoma treatment, seeking new and innovative strategies to combat this disease.

Date :
  1. Date Completed 2019-01-28
  2. Date Revised 2019-01-28
Further Info :

Pubmed ID

30320355

DOI: Digital Object Identifier

10.3892/mmr.2018.9537

Related Literature

Article Analysis
・Effects of vemurafenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.